Bad Blood Book Pdf

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Bad blood book pdf Continue NEW YORK TIMES BEST SELLER - NAMED ONE OF THE BEST BOOKS OF THE YEAR BY: NPR, The New York Times Book Review, Time, Wall Street Journal, Washington Post - The McKinsey Business Book of the Year The FULL Inside Story of the breathtaking rise and shocking collapse of Theranos, a different multibillion-dollar biotech startup founded by Elizabeth Holmes, history is even crazier than I expected. This book has it all: complex fraud, corporate intrigue, magazine covers, shattered family relationships, and the demise of a company once valued at nearly $10 billion - Bill Gates In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as a woman by Steve Jobs: a brilliant Stanford dropout whose unicorn startup promised to revolutionize the medical industry with a machine that would make blood testing much easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes worth about $4.7 billion. A fascinating story of the largest corporate fraud since Enron, a story about ambition and arrogance set against the backdrop of Silicon Valley's bold promises. 2018 book by John Kerryr Bad Blood: Secrets and Lies in Silicon Valley Startup AuthorJohn CarreyrouSubjectTheranosPublished21 May 2018PublisherAlfred A. KnopfISBN978-1-5247-3165-6OCLC1029779381Dewey Decimal338.7/681761LC ClassHD99995.H423 U627 2018 Bad Blood: Secrets and Lies in a Silicon Valley Startup - this is a scientifically popular journalist John Kerry, released on May 21, 2018. It covers the rise and fall of Theranos, a multibillion-dollar biotech startup led by Elizabeth Holmes. The book received critical acclaim, winning the Financial Times and McKinsey Business Book of the Year Award in 2018. In 2018, the production was a movie version starring Jennifer Lawrence, written by Vanessa Taylor and directed by Adam McKay. In late 2015, Kerriru began a series of investigative articles about Theranos published in The Wall Street Journal about a blood test startup founded by Elizabeth Holmes. The articles have questioned the company's claim to be able to run a wide range of laboratory tests from a tiny blood sample from a finger prick. In May 2018, Bad Blood: Secrets and Lies in a Silicon Valley Startup was published by Knopf. Critical reception While Roger Lowenstein of The New York Times acknowledged that Kerriru's presentation has several minor flaws - like excessive amounts of characters and sometimes reliance on stereotypes - the paper concludes that such spots are in place. diminishes the power of Bad Blood, and that the author convincingly recounts how he got involved and remarkably candid about his craft. He added: The author's description of Holmes as a manic leader who found himself cold-bloodedly hostile when challenged is a mature material for a psychologist; Kerriru wisely allows the evidence to speak for itself. Kevin Nguyen of G magazine also called the report to Kerriru... Exhaustive, including an interview with more than 150 people, and said: The book stumbles a bit in its third act, when Kerriru introduces himself and how he broke the story . However, he continued by saying that these are small questions in the book that speaks volumes about technology in general, and that Bad Blood is a satisfying read for those who want a book full of obscene startupenfreude. Charles Harry of the Library Journal said: Kerrir's well-written and accessible work can be compared to another outstanding business expose, James B. Stewart's The Thief's Den, and is highly recommended for all collections. Danny Crichton of TechCrunch said, Kerrir's shaky and fearless reporting to The Wall Street Journal will eventually expose one of the biggest frauds ever committed in Silicon Valley... And yet, what I found in the book was not all that exciting or shocking, but amazingly pedestrian. He explained: Carrair's laconic WSJ tone, with its simple facts attitude... punctuated only occasionally by brief interludes about the motives and psychology of his characters, and that he lacks the sort of verve that makes business thrillers like Barbarians at the Gate or Red Notice so engaging. Bill Gates said: Bad Blood solves some serious ethical issues, but ultimately it's a thriller with a tragic ending. It's fun to read full of strange details that will make you gasp out loud. The book has been included in end-of-year lists, including the 28 Most Unforgettable Books of 2018, NPR's Guide to Great Readings of 2018 and 100 Famous Books of 2018 and The New York Times Book Review, 100 famous books of 2018. The book also won the Financial Times and McKinsey Business Book of the Year 2018. John Kerryr(May 21, 2018). Bad Blood: Secrets and Lies at a Silicon Valley startup. Penguin Random House. ISBN 9781524731656. References to quotes - b Lowenstein, Roger (May 21, 2018). 'Bad Blood' review: How one company cheated Silicon Valley. And how he got caught. The New York Times. Received on March 30, 2019. Dave McNary,23, 2016. Legendary Winning Bidding War for Jennifer Lawrence's film Bad Blood. Different. Archive from the original for 2016-06-25. Received on July 23, 2018. James B. Stewart, October 29, 2015. Frays narration for Theranos and Elizabeth Holmes. The New York Times. Received on January 31, 2016. John Kerriro (October 16 (g.). Hot Hot Theranos has struggled with its blood test technology. Wall Street Journal. Received on January 31, 2016. John Kerryra (December 27, 2015). In Theranos, many strategies and snags. Wall Street Journal. Received on January 31, 2016. Kevin Nguyen (May 21, 2018). 'Bad Blood' exposes the biggest scam in Silicon Valley Gq. Received March 30, 2019. Harry, Charles (June 15, 2018). Bad Blood: Secrets and Lies at a Silicon Valley startup. Library magazine. 143 (11): 78–83. Crichton, Danny. In bad blood, a pedestrian tale of his story and lies. Techcrunch. Received on March 30, 2019. Bill Gates (December 3, 2018). I couldn't put this thriller with a tragic ending. gatesnotes.com. received on March 30, 2019. Suzanne Kahalan; Dawson, Mackenzie (December 14, 2018). 28 most memorable books of 2018. New York Post. received on March 31, 2019. Elizabeth Baker (November 27, 2018). NPR Concierge Book: Our Guide to 2018 Great Readings. Npr. Received March 31, 2019. NYTimes Famous Non-Fiction Book 2018 Penguin Random House. Penguin Random House. Received March 31, 2019. Andrew Hill (November 12, 2018). Bad Blood wins the FT and McKinsey Business Book 2018. Financial Times. Received on November 12, 2018. Bad blood. Book signs. Received on November 10, 2018. The work is cited by Kerrir, John (2018). Bad Blood: Secrets and Lies in Silicon Valley Launch (New York First: Knopf. ISBN 9781524731656. OCLC 1029779381. Extracted from The Financial Times and McKinsey Business Book of the Year by The New York Times Notable Book Washington Post Notable Book One of the Best Books of the Year: NPR, San Francisco Chronicle, Time, Esquire, Fortune, Marie Claire, GH, Psychic Floss, Science Friday, Bloomberg, Popular Mechanics, BookRiot, Seattle Times, Oregonian, Publishers Weekly, Library Magazine In 2014, Theranos founder and CEO Elizabeth Holmes was widely regarded as the next Steve Jobs: a brilliant Stanford dropout whose startup unicorn promised to revolutionize the medical industry. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a round of fundraising that valued the company at more than $9 billion, putting Holmes worth about $4.5 billion. Mistaken results put patients at risk, leading to misdiagnosis and unnecessary treatment. All the while, Holmes and her partner, Sunny Balvani, worked to silence anyone who expressed fears, from journalists to their employees. Strictly reported and fearlessly written, Bad Blood is a gripping story corporate corporate because Enron is a story about ambition and arrogance set against the backdrop of Silicon Valley's bold promises. ISBN-13: 9780525431992 Publisher: Knopf Doubleday Publishing Group Publish Date: 01/28/2020 Pages: 368 Sales Division: 6058 Product Sizes: 5.10 (w) x 7.90 (h) x 0.90 (d) Note author ixPrologue 31 Purposeful Life 92 Claybot 183 Envy Apple 304 Goodbye East Paly 41B Childhood Neighbor 546 Sunny 677 Dr. J 818 miniLab 959 Wellness Play 10910 Who's L Boot? 12011 Lighting Fuisz 13212 Ian Gibbons 14113 Chiat'Day 15014 Going Live 16115 Unicorn 17416 Grandson 18417 Glory 20118 Hippocratic Oath 21319 Council 22320 Ambush 24 021 Trade Secrets 25022 La Mattanza 25923 Damage Management 26824 Empress has No Clothes 281Epilogue 294After to Vintage Books Edition 300Acknowledgments 303Notes 307Index 327 Great and at times almost incredible story. Theranos may be the largest case of corporate fraud since Enron. - New York Cooling . Reads like a thriller... Kerriru tells Theranos story almost to perfection. - The New York Times Book Review Gripping . Riveting.... Said with an impulse worthy of a crime novel. - Los Angeles Review of Riveting Books . For all its booming feel, there are eternal aspects of Theranos history. Venality is age-old, but so is courage, and that of the former employees who blew the whistle on his deceptions is restorative . And more than an honorable mention should go to Carreyrou, a dogged old-school reporter uncowed by Theranos' legal hardball. - San Francisco Chronicle Engrossing . It's hard to put down . He brags about film scenes detailing . Theranos staff history is a hero, with the power of journalism not far behind. -Science This page turning . Capture.... Presents comprehensive evidence of fraud committed by Theranos Chief Executive Elizabeth Holmes... Reveals many dark secrets of Theranos that have not previously been exposed. - Nature It's staying all night to read a book that's just as impulsive, shocking, and riveting as the best thrillers.
Recommended publications
  • Bad Blood Secrets and Lies in a Silicon Valley Startup by John Carreyrou

    Bad Blood Secrets and Lies in a Silicon Valley Startup by John Carreyrou

    Bad Blood Secrets and Lies in a Silicon Valley Startup By John Carreyrou At its peak in 2013/14, Theranos had a valuation of $10 billion, representing incredible growth in the 10 years since its incorporation in 2003. The company claimed that it had developed and commercialized a revolutionary new blood testing solution. Viewed as a stunning start-up success, the Theranos board was a roster of well-known government and business leaders, including Henry Kissinger, James Mattis and Riley Bechtel. The buzz around Theranos was electric, and high-profile investors such as Betsey DeVos, the Walton family, and Rupert Murdoch invested hundreds of millions of dollars to fund the company. At the helm was Elizabeth Holmes, founder and CEO. Holmes dropped out of Stanford Engineering in 2004 and used her tuition fees to help fund her brainchild. Blond, attractive, and possessed of an unusually deep baritone voice, Holmes was listed by Forbes as one of America’s Richest Self-Made Women in 2015, with a net worth of over $4 billion. That same year, however, it all came crashing down when investigative reporter John Carreyrou of the Wall Street Journal revealed that the Theranos technology did not work as claimed. Carreyrou’s exhaustive research uncovered a web of lies and cover-ups, dating back to the earliest days at Theranos. Today, the company is worth nothing and has been dissolved, investors have lost multi- millions, and Elizabeth Holmes was charged with massive fraud by the SEC in March, 2018. This riches-to-rags story has captured the public’s imagination, and a movie based on Carreyrou’s book (starring Jennifer Lawrence as Elizabeth Holmes), is slated for release in 2020.
  • How Innovation Works a Bright Future Not All Innovation Is Speeding up the Innovation Famine China’S Innovation Engine Regaining Momentum

    How Innovation Works a Bright Future Not All Innovation Is Speeding up the Innovation Famine China’S Innovation Engine Regaining Momentum

    Dedication For Felicity Bryan Contents Cover Title Page Dedication Introduction: The Infinite Improbability Drive 1. Energy Of heat, work and light What Watt wrought Thomas Edison and the invention business The ubiquitous turbine Nuclear power and the phenomenon of disinnovation Shale gas surprise The reign of fire 2. Public health Lady Mary’s dangerous obsession Pasteur’s chickens The chlorine gamble that paid off How Pearl and Grace never put a foot wrong Fleming’s luck The pursuit of polio Mud huts and malaria Tobacco and harm reduction 3. Transport The locomotive and its line Turning the screw Internal combustion’s comeback The tragedy and triumph of diesel The Wright stuff International rivalry and the jet engine Innovation in safety and cost 4. Food The tasty tuber How fertilizer fed the world Dwarfing genes from Japan Insect nemesis Gene editing gets crisper Land sparing versus land sharing 5. Low-technology innovation When numbers were new The water trap Crinkly tin conquers the Empire The container that changed trade Was wheeled baggage late? Novelty at the table The rise of the sharing economy 6. Communication and computing The first death of distance The miracle of wireless Who invented the computer? The ever-shrinking transistor The surprise of search engines and social media Machines that learn 7. Prehistoric innovation The first farmers The invention of the dog The (Stone Age) great leap forward The feast made possible by fire The ultimate innovation: life itself 8. Innovation’s essentials Innovation is gradual Innovation is different from invention Innovation is often serendipitous Innovation is recombinant Innovation involves trial and error Innovation is a team sport Innovation is inexorable Innovation’s hype cycle Innovation prefers fragmented governance Innovation increasingly means using fewer resources rather than more 9.
  • Bad Blood : Secrets and Lies in a Silicon Valley Startup / John Carreyrou

    Bad Blood : Secrets and Lies in a Silicon Valley Startup / John Carreyrou

    THIS IS A BORZOI BOOK PUBLISHED BY ALFRED A. KNOPF Copyright © 2018 by John Carreyrou All rights reserved. Published in the United States by Alfred A. Knopf, a division of Penguin Random House LLC, New York, and distributed in Canada by Random House of Canada, a division of Penguin Random House Canada Limited, Toronto. www.aaknopf.com Knopf, Borzoi Books, and the colophon are registered trademarks of Penguin Random House LLC. Library of Congress Cataloging-in-Publication Data Names: Carreyrou, John, author. Title: Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou. Description: First Edition. | New York : Knopf, 2018. Identifiers: LCCN 2018000263 | ISBN 9781524731656 (hardback) | ISBN 9781524731663 (ebook) Subjects: LCSH: Theranos (Firm)—History. | Hematologic equipment industry—United States. | Fraud—United States. | BISAC: BUSINESS & ECONOMICS / Entrepreneurship. | BUSINESS & ECONOMICS / Finance. | TECHNOLOGY & ENGINEERING / Biomedical. Classification: LCC HD9995.H423 U627 2018 | DDC 338.7/681761—dc23 LC record available at https://lccn.loc.gov/2018000263 Ebook ISBN 9781524731663 Cover design by Tyler Comrie v5.2_r1 ep Contents Cover Title Page Copyright Dedication Author’s Note Prologue 1. A Purposeful Life 2. The Gluebot 3. Apple Envy 4. Goodbye East Paly 5. The Childhood Neighbor 6. Sunny 7. Dr. J 8. The miniLab 9. The Wellness Play 10. “Who Is LTC Shoemaker?” 11. Lighting a Fuisz 12. Ian Gibbons 13. Chiat\Day 14. Going Live 15. Unicorn 16. The Grandson 17. Fame 18. The Hippocratic Oath 19. The Tip 20. The Ambush 21. Trade Secrets 22. La Mattanza 23. Damage Control 24. The Empress Has No Clothes Epilogue Acknowledgments Notes About the Author For Molly, Sebastian, Jack, and Francesca Author’s Note This book is based on hundreds of interviews with more than 150 people, including more than sixty former Theranos employees.
  • 9/6/2017 Hot Startup Theranos Has Struggled with Its Blood-Test Technology - WSJ

    9/6/2017 Hot Startup Theranos Has Struggled with Its Blood-Test Technology - WSJ

    9/6/2017 Hot Startup Theranos Has Struggled With Its Blood-Test Technology - WSJ DOW JONES, A NEWS CORP COMPANY DJIA ▲ 21830.88 0.36% S&P 500 ▲ 2466.31 0.34% Nasdaq ▲ 6393.57 0.28% U.S. 10 Yr ▼ -11/32 Yield 2.099% Crude Oil ▲ 49.13 0.97% This copy is for your personal, non­commercial use only. To order presentation­ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. http://www.wsj.com/articles/theranos­has­struggled­with­blood­tests­1444881901 TECH Silicon Valley lab, led by Elizabeth Holmes, is valued at $9 billion but isn’t using its technology for all the tests it offers Elizabeth Holmes, Theranos's founder, chairman and chief executive, at the blood­testing company's headquarters in Palo Alto, Calif. Her ownership stake in Theranos is valued at more than $4.5 billion. PHOTO: MARTIN E. KLIMEK By John Carreyrou Updated Oct. 16, 2015 3:20 p.m. ET On Theranos Inc.’s website, company founder Elizabeth Holmes holds up a tiny vial to show how the startup’s “breakthrough advancements have made it possible to quickly process the full range of laboratory tests from a few drops of blood.” The company offers more than 240 tests, ranging from cholesterol to cancer. It claims its technology can work with just a finger prick. Investors have poured more than $400 million into Theranos, valuing it at $9 billion and her majority stake at more than half that. The 31-year-old Ms. Holmes’s bold talk and black turtlenecks draw comparisons to Apple Inc.
  • Bad Blood Secrets and Lies in a Silicon Valley Startup

    Bad Blood Secrets and Lies in a Silicon Valley Startup

    Bad Blood Secrets and Lies in a Silicon Valley Startup By John Carreyrou www.thebusinesssource.com All Rights Reserved © At its peak in 2013/14, Theranos had a valuation of $10 billion, representing incredible growth in the 10 years since its incorporation in 2003. The company claimed that it had developed and commercialized a revolutionary new blood testing solution. Viewed as a stunning start-up success, the Theranos board was a roster of well-known government and business leaders, including Henry Kissinger, James Mattis and Riley Bechtel. The buzz around Theranos was electric, and high-profile investors such as Betsey DeVos, the Walton family, and Rupert Murdoch invested hundreds of millions of dollars to fund the company. At the helm was Elizabeth Holmes, founder and CEO. Holmes dropped out of Stanford Engineering in 2004 and used her tuition fees to help fund her brainchild. Blond, attractive, and possessed of an unusually deep baritone voice, Holmes was listed by Forbes as one of America’s Richest Self-Made Women in 2015, with a net worth of over $4 billion. That same year, however, it all came crashing down when investigative reporter John Carreyrou of the Wall Street Journal revealed that the Theranos technology did not work as claimed. Carreyrou’s exhaustive research uncovered a web of lies and cover-ups, dating back to the earliest days at Theranos. Today, the company is worth nothing and has been dissolved, investors have lost multi-millions, and Elizabeth Holmes was charged with massive fraud by the SEC in March, 2018. This riches-to-rags story has captured the public’s imagination, and a movie based on Carreyrou’s book (starring Jennifer Lawrence as Elizabeth Holmes), is slated for release in 2020.
  • Tahák K Audioknize Zlá Krev Přehled Nejdůležitějších Osob a Jejich Vzájemných Vztahů

    Tahák K Audioknize Zlá Krev Přehled Nejdůležitějších Osob a Jejich Vzájemných Vztahů

    Tahák k audioknize Zlá krev Přehled nejdůležitějších osob a jejich vzájemných vztahů. Aaron Moor, zaměstnanec a konstruktér v Theranosu. Alan Beam, ředitel laboratoře Theranosu a důvěrný zdroj Johna Carreyroua (autora). Ana Arriolová, zaměstnankyně Applu, kterou Elizabeth přetáhla do Theranosu, kde působila jako šéfdesignérka odpovědná za celkový vzhled Edisonu. Anjali Laghariová, chemička, dlouholetá zaměstnankyně Theranosu a kolegyně Iana Gibbonse. Avie Tevanian, bývalý kolega Any Arriolové z Applu, člen představenstva a investor Theranosu, patřící mezi nejstarší a nejbližší přátele Steva Jobse. Daniel Young, bioinženýr s doktorátem z MIT, pracující v Theranosu v oblasti prediktivního modelování, následně šéf oddělení biomatematiky Theranosu. David Boies, slavný advokát, zastupující Theranos v kauze proti Richardu Fuiszovi. David Doyle, podnikový právník Theranosu. David Shoemaker, podplukovník, zástupce vojenská delegace rozhodující o testovacích přístrojů na válčišti v Afghánistánu. Diana Dupuyová, pracovnice laboratoře Theranosu. Donald L. Lucas, zvaný Don, předseda představenstva Theranosu, investor rizikového kapitálu a poradce Elizabeth. Edmond Ku, zvaný Ed, známý technik startupů v Silicon Valley, vedoucí oddělení konstrukce Theranosu. Elizabeth Holmesová, majitelka a zakladatelka Theranosu. Erika Cheungová, zaměstnankyně Theranosu a kolegyně Tylera Shultze, pracující mimo jiné na validačních experimentech Edisonu. Gary Frenzel, šéf týmu chemiků v Theranosu. Gary Yamamoto, zkušený terénní inspektor sanfranciské pobočky CMS. George
  • Consolidated Class Action Complaint 22 Jury Trial Demanded 23 24 25 26 27 28

    Consolidated Class Action Complaint 22 Jury Trial Demanded 23 24 25 26 27 28

    Case 2:16-cv-02138-HRH Document 88 Filed 11/22/16 Page 1 of 89 Lynn Lincoln Sarko (pro hac vice) 1 T. David Copley Gretchen Freeman Cappio (pro hac vice) 2 KELLER ROHRBACK L.L.P. 1201 Third Ave., Ste. 3200 3 Seattle, WA 98101 Telephone: (206) 623-1900 4 Facsimile: (206) 623-3384 Email: [email protected] 5 Email: [email protected] Email: [email protected] 6 Michael W. Sobol (pro hac vice) 7 Roger N. Heller (pro hac vice) LIEFF CABRASER HEIMANN 8 & BERNSTEIN, LLP 275 Battery Street, 29th Floor 9 San Francisco, CA 94111-3339 Telephone: (415) 956-1000 10 Facsimile: (415) 956-1008 Email: [email protected] 11 Email: [email protected] 12 Interim Co-Lead Plaintiffs’ Counsel 13 [Additional counsel listed on signature page] 14 15 UNITED STATES DISTRICT COURT 16 DISTRICT OF ARIZONA 17 In re: No. 2:16-cv-2138-HRH (Consolidated with) 18 Arizona THERANOS, INC., No. 2:16-cv-2373-HRH Litigation No. 2:16-cv-2660-HRH 19 No. 2:16-cv-2775-HRH -and- 20 No. 2:16-cv-3599-HRH 21 CONSOLIDATED CLASS ACTION COMPLAINT 22 JURY TRIAL DEMANDED 23 24 25 26 27 28 Case 2:16-cv-02138-HRH Document 88 Filed 11/22/16 Page 2 of 89 TABLE OF CONTENTS 1 2 I. INTRODUCTION .................................................................................................. 1 3 II. JURISDICTION AND VENUE ............................................................................. 4 4 III. PARTIES ................................................................................................................ 5 5 IV. FACTUAL BACKGROUND ................................................................................ 7 6 A. Theranos ...................................................................................................... 7 7 8 B. Walgreens Knowingly Ignored Repeated Red Flags About the Reliability of Theranos’s Testing .............................................................. 10 9 10 C.
  • THE WALL STREET JOURNAL. U

    THE WALL STREET JOURNAL. U

    THE WALL STREET JOURNAL. u TESTING THERANOS A hot laboratory startup hits snags Popular Investment Same Patient, Different Results Theranos has raised at least For one Arizona woman, Theranos found abnormally high levels for six $750 million from investors. tests. Hospital tests two days later were normal. Theranos says variation across labs is commonplace and can be caused by medicines and diet. $600 million Theranos result Hospital result Normal range* Test Results 8.3 10.6 Calcium† 9.2 11.8 400 5.7 8.3 Protein, total‡ 6.8 8.4 44 135 Alkaline phosphatase** 100 149 Alanine 841 200 aminotransferase** 35 47 Aspartate 035 aminotransferase** 34 56 73 99 0 Glucose† 99 103 Dec. Feb. Oct. June Feb. 2004 ’06 ’06 ’10 ’14 *As stated by Theranos †in milligrams per deciliter ‡in grams per deciliter **liver enzyme test, in units per liter Source: Company filings Sources: Theranos and HonorHealth Scottsdale Shea Medical Center via Nicole Sundene and THE WALL STREET JOURNAL. Maureen Glunz THE WALL STREET JOURNAL. TESTING THERANOS A Prized Startup’s Struggles By John Carreyrou October 15, 2015 Theranos’s Growing Pains By John Carreyrou December 28, 2015 Hot Startup Dials Back Lab Tests at FDA’s Behest By John Carreyrou October 16, 2015 Walgreens Scrutinizes Theranos By Michael Siconolfi, John Carreyrou and Christopher Weaver October 24, 2015 Safeway, Theranos Split After $350 Million Deal By John Carreyrou November 11, 2015 FDA Raps Lab Startup Theranos By John Carreyrou October 28, 2015 Theranos Remains in ‘Pause Period’ By John Carreyrou October 22, 2015 U.S. Probes Theranos Complaints By John Carreyrou December 21, 2015 Theranos Searches for Director to Oversee Laboratory By John Carreyrou November 6, 2015 Theranos Authorizes New Stock, Filing Says By Rolfe Winkler and John Carreyrou October 29, 2015 TESTING THERANOS A Prized Startup’s Struggles Silicon Valley lab Theranos is valued at $9 billion but isn’t using its technology for all the tests it offers MARTIN E.
  • Book-Review-April 2020

    Book-Review-April 2020

    BLL Book Reviews - Apil 2020 Brewster Ladies Library, 1822 Main Street, Brewster, MA 02631 In this issue… Welcoming Elijah: A Passover Tale with a Tail (Picture Book for 5-8 year-olds) by Leslea Newman and illustrated by Susan Gal (Nori Morganstein) The Last Train to London by Meg Waite Clayton (Susan Carr) A Very Stable Genius: Donald J. Trump’s Testing of America by Philip Rucker and Carol Leonnig (Jim Mills) Factfulness: Ten Reasons We’re Wrong about the World and Why Things are Better Than You Think by Hans Rolfing and others (Stuart J. Bassin) Call Sign Chaos by Jim Mattis and Bing West (Don Boink) Tightrope: Americans Reaching for Hope by Nicholas D. Kristof and Sheryl WuDunn (Don Boink)* Tightrope: Americans Reaching for Hope by Nicholas D. Kristof and Sheryl WuDunn (Jim Mills)* Time To Build by Yuval Levin (Don Boink) Bad Blood by John Carreyrou (Susan Carr) A Bookshop in Berlin by Francoise Frenkel (Jim Mills) Robbing Bees: A Biography of Honey, the Sweet Liquid Gold that Seduced the World by Holley Bishop (Jim Mills) * When two of our reviewers review the same book, we print both reviews. Welcoming Elijah: A Passover Tale with a Tail (Picture Book for 5-8 year-olds) (Charlesbridge, 2020) by Leslea Newman and illustrated by Susan Gal reviewed by: Nori Morganstein, Youth Services Librarian/Assistant Director I’m not always a fan of Children’s holiday books. For starters, I like books that celebrate everyone. I would hate for any child to feel like they weren’t included in a story.
  • Technology and the Lab: Lessons Learned

    Technology and the Lab: Lessons Learned

    Truths and Falsehoods of New Clinical Lab Technology: What do Theranos and Successful Inventions have in Common? Presenter: Dr. Mike Astion Medical Director, Dept. of Laboratories Seattle Children’s Hospital Answer Theranos and successful lab inventions are both examples of the law of sowing (planting) and reaping (harvesting). The outcomes of both are predicted by principles of laboratory science, history, and management. This is everything I know about directing a lab. 1. Avoid extreme thinking • The sky is not falling • Healthcare is not ending. • Everything is going to be OK. 2. Less is more in nearly all lab endeavors. 3. Innovation is manageable. ….what I know (continued) 4. Most people come to work to do a good job. 5. This is a good and honorable career. 6. Cake and pizza are both good ideas. 7. Venous blood is a very good specimen. 8. In the battle between “being right” and “being effective”, choose “being effective”. Theranos claims • 300 tests from a few drops of finger stick blood • Breakthrough technology • Very inexpensive • The future of lab testing is that “more is better” meaning that more testing per patient is better in both wellness and illness settings. A Theranos Timeline By THE NEW YORK TIMES, JULY 8, 2016 2003: Elizabeth Holmes drops out of Stanford to start Theranos in 2003 July 2010: Theranos raises $45 million by selling equity. It is privately held. May 2013: Dr. Ian Gibbons, a principle scientist at Theranos, commits suicide. July 2013. Theranos board: Richard M. Kovacevich, CEO, Wells Fargo; Gen. James Mattis, ; Henry A. Kissinger; former Senator Samuel Nunn; former secretary of state George P.